Price
$4.47
Increased by +3.71%
Dollar volume (20D)
5.11 M
ADR%
4.00
Earnings report date
Nov 5, 2024
Shares float
135.51 M
Shares short
6.06 M [4.48%]
Shares outstanding
188.78 M
Market cap
813.65 M
Beta
1.91
Price/earnings
N/A
20D range
3.68 4.72
50D range
3.05 4.72
200D range
1.79 4.72

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States.

Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.

The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.

It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300.

The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.

Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Aug 1, 24 -0.11
Decreased by -10.00%
-0.10
Decreased by -10.00%
May 2, 24 -0.10
Increased by 0.00%
-0.11
Increased by +9.09%
Feb 29, 24 -0.12
Increased by +14.29%
-0.12
Nov 7, 23 -0.12
Increased by 0.00%
-0.11
Decreased by -9.09%
Aug 3, 23 -0.10
Increased by 0.00%
-0.11
Increased by +9.09%
May 4, 23 -0.10
Increased by +9.09%
-0.14
Increased by +28.57%
Mar 2, 23 -0.14
Increased by +6.67%
-0.13
Decreased by -7.69%
Nov 9, 22 -0.12
Increased by +50.00%
-0.13
Increased by +7.69%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 1.53 M
Decreased by -77.09%
-17.88 M
Decreased by -15.60%
Decreased by -1.17 K%
Decreased by -404.57%
Dec 31, 23 2.15 M
Decreased by -65.65%
-19.31 M
Increased by +15.71%
Decreased by -900.33%
Decreased by -145.41%
Sep 30, 23 4.66 M
Decreased by -21.74%
-20.10 M
Decreased by -16.05%
Decreased by -431.60%
Decreased by -48.29%
Jun 30, 23 4.65 M
Decreased by -67.34%
-17.09 M
Decreased by -19.75%
Decreased by -367.53%
Decreased by -266.66%
Mar 31, 23 6.69 M
Decreased by -46.85%
-15.46 M
Increased by +1.92%
Decreased by -231.24%
Decreased by -84.54%
Dec 31, 22 6.25 M
Increased by +94.79%
-22.91 M
Decreased by -7.46%
Decreased by -366.87%
Increased by +44.83%
Sep 30, 22 5.95 M
Increased by +78.20%
-17.32 M
Increased by +9.58%
Decreased by -291.05%
Increased by +49.26%
Jun 30, 22 14.24 M
Increased by +511.46%
-14.28 M
Increased by +26.37%
Decreased by -100.24%
Increased by +87.96%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY